Adverts

Open Access Articles- Top Results for Mebutamate

Mebutamate

</th></tr>
Mebutamate
File:Mebutamate.svg
Systematic (IUPAC) name
2-sec-Butyl-2-methylpropane-1,3-diyl dicarbamate
Clinical data
Identifiers
64-55-1 7pxN
N05BC04
PubChem CID 6151
ChemSpider 5919 7pxN
UNII 5H8F175RER 7pxY
KEGG D01807 7pxY
ChEMBL CHEMBL1200922 7pxN
Chemical data
Formula C10H20N2O4
232.277 g/mol
 14pxN (what is this?)  (verify)

Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class.[1][2] It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.[3]

Mebutamate is one of many GABAergic drugs which act via allosteric agonism of the GABAA receptor at the β-subreceptor similair to barbiturates. In contrast, benzodiazepines act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.

Other carbamates with the same mechanism of action and pharmacological properties include meprobamate, carisoprodol, felbamate, and tybamate).

Synthesis

File:Mebutamate synthesis.svg
Mebutamate synthesis: Berger, Ludwig, U.S. Patent 2,878,280 (1959 to Carter Prod.).

Structural analogs

References

  1. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. p. 634. ISBN 978-3-88763-075-1. 
  2. The Merck Index (14 ed.). Merck Publishers. 5813. ISBN 978-0-911910-00-1. 
  3. Tetreault, L.; Richer, P.; Bordeleau, J. M. (1967). "Hypnotic properties of mebutamate: A comparative study of mebutamate, secobarbital and placebo in psychiatric patients". Canadian Medical Association journal 97 (8): 395–398. PMC 1923261. PMID 6037393.  edit


Lua error in package.lua at line 80: module 'Module:Buffer' not found.